|
Wednesday 5th April 2023 |
Text too small? |
Calocurb operates in the natural supplement part of the Life Sciences and Medical Technology sector. It specialises in appetite management, using a unique active ingredient sourced from New Zealand hops believed to be the only natural, non-prescriptive alternative to highly expensive prescription drugs to assist people with chronic and debilitating obesity. Calocurb was formed in 2017, and is classified as early stage, with its technology origins being from Plant and Food Research.
BIF will make a cash investment of $250,000. Following this transaction (and issue of additional units to fund the purchase), Calocurb will represent 1.7% of BIF’s investment portfolio of 32 companies, and with a net asset value of over $14.5 million.
Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund’s Product Disclosure Statement (PDS) that is available at www.booster.co.nz
For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-innovation-fund.aspx
For more information, please contact:
Gary Scott
Company Secretary
Booster Investment Management Limited
04 8944300
About Booster
Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of the Booster Group which has been helping New Zealanders save since 1998. The group currently administers superannuation and investment funds of over $5 billion on behalf of more than 170,000 New Zealanders.
BIF is a managed investment fund that invests in early-stage companies founded on intellectual property originated or developed in New Zealand.
For more information, including a copy of the Product Disclosure Statement, please visit www.booster.co.nz
BIF acquires shares in Calocurb
No comments yet
SPG - FY26 Annual Results
PYS - PaySauce FY26 Full Year Result and Annual Report
IFT - Infratil Full Year Results for the year ended 31 March 2026
May 27th Morning Report
RYM - FY26 marks significant year of progress
FPH reports strong revenue and profit growth for FY26
IFT - Infratil Full Year Results for the year ended 31 March 2026
PEB - Advancing Medicare Coverage Goals; Cost Contained
TRU - TruScreen Completes Oversubscribed Placement
EROAD Continues Transformation, Reports FY26 Results